N環球 N GLOBE
Canada · Health

Health Canada approves first daily GLP-1 weight-loss pill; pharmacies expected to stock it in January

· N GLOBE

Health Canada authorized Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) on November 13, Canada's first once-daily weight-loss pill, offering an alternative to weekly injections; Lilly expects it in Canadian pharmacies in January.

Health Canada has authorized Eli Lilly's oral weight-loss drug Foundayo (active ingredient orforglipron), Canada's first once-daily GLP-1 weight-loss pill, giving patients who do not want weekly injections a new option. The drug was authorized on November 13, and Lilly expects it to reach Canadian pharmacies in January.

Above: file photo of weight-loss medication. (Photo: Medscape)

One pill a day instead of a weekly injection

Foundayo is an oral small-molecule GLP-1 receptor agonist taken once a day, in capsules of six strengths from 1 to 36 mg, starting at 1 mg a day and rising in steps. Unlike weekly injectables such as Ozempic and Wegovy, it can be swallowed without being broken down by the digestive system. It is approved for adults with obesity (a body mass index of 30 or more), or who are overweight (BMI of 27 or more) with at least one weight-related condition such as high blood pressure or sleep apnea, and for adults with type 2 diabetes, alongside a healthy diet and more exercise.

January launch; reimbursement still undecided

Lilly spokesperson Ethan Pigott said the company expects the capsules to be available in Canadian pharmacies in January. In the United States, Foundayo was approved by the Food and Drug Administration on April 1 this year, as tablets. No Canadian price has been announced. Notably, Lilly withdrew its weight-management reimbursement review from Canada's Drug Agency on October 23, meaning public coverage for weight loss is unlikely in the near term; the type 2 diabetes review continues, with an expert committee due to meet on December 16.

Experts: heart protection still unproven

Experts note that whether orforglipron protects the heart the way semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide do still awaits clinical trial results. Novo Nordisk's Wegovy pill is still awaiting Health Canada approval.

Sources: The Canadian Press, Health Canada product monograph, Canada's Drug Agency.

💬 Comments

No comments yet. Be the first!